Evidence map›Paper›PMID 41015804›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025

Jingui Shenqi pill ( ) treats cardiorenal syndrome by inhibiting mitogen-activated protein kinase signaling pathway and reducing inflammatory response.

Huang Shuyan, Ding Xinyue, Zhang Hui, Liu Zongjun, Luan Yuling, Xing Lina

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huang ShuyanInstitute of Cardiovascular Translational Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200300, China.
Ding XinyueInstitute of Cardiovascular Translational Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200300, China.
Zhang HuiInstitute of Cardiovascular Translational Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200300, China.
Liu ZongjunInstitute of Cardiovascular Translational Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200300, China.
Luan YulingInstitute of Cardiovascular Translational Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200300, China.
Xing LinaInstitute of Cardiovascular Translational Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200300, China.

Funding

Chengdu University of Traditional Chinese Medicine "Xinglin Scholar" Discipline Talent Research Enhancement Plan: Based on provirus integration site for moloney murine leukemia virus 3 to Explore the Molecular Mechanism of Jingui Shenqi pill in Regulating Water Metabolism in Renal Tubular Cells YYZX2022165Clinical Advantage Discipline of Health System of Putuo District in Shanghai 2019ysxk01Shanghai Putuo District Health System Science and Technology Innovation Project: Study on the Effect and Mechanism of Jinkui Shenqi Pills on Renal Water Metabolismprovirus integration site for moloney murine leukemia virus 3/aquaporin 2 Regulation PTKWS202104
6 · The paper itself

Abstract

objectiveTo confirm the therapeutic effect and mechanism of Jingui Shenqi pill (, JGSQP) on cardiorenal syndrome.

methodsDoxorubicin was used to build heart-kidney coinjury rat model. After the modeling was completed, JGSQP gavage intervention was performed. The cardiac function of rats in each group was evaluated by ultrasound detection. Serum of rats was collected and examined for markers of heart and kidney damage. Enzyme linked immunosorbent assay detected serum inflammatory factors interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) expression. Quantitative real-time polymerase chain reaction (PCR) and Western blot detected the changes of related genes and proteins.

resultsJGSQP significantly increased left ventricular ejection fraction (EF) and left ventricular shortening fraction (FS) values, decreased the heart and kidney damage markers and fibrosis levels (

conclusionsJingui Shenqi pill can exert therapeutic effects on cardiorenal syndrome by inhibiting the activation of the MAPK signaling pathway and inflammatory responses.

Indexed as

Cardio-Renal SyndromeDrugs, Chinese HerbalMAP Kinase Signaling SystemMitogen-Activated Protein KinasesAnimalsHumansInterleukin-1betaInterleukin-6MaleRatsRats, Sprague-DawleyTumor Necrosis Factor-alphaDrugs, Chinese HerbalInterleukin-1betaInterleukin-6Mitogen-Activated Protein KinasesshenqiTumor Necrosis Factor-alphacardiorenal syndromeinflammatory cytokinesJingui Shenqi pillmitogen-activated protein kinasesignal transduction

Identifiers

PMID41015804
PMCPMC12454269

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.